The role of alisertib in treatment of peripheral T-cell lymphomas.

Abstract

Peripheral T-cell lymphomas are aggressive lymphomas with poor outcomes for which novel treatments are urgently needed. Alisertib (MLN8237) is a second-generation oral Aurora A kinase inhibitor. Treatment with alisertib results in an accumulation of cells with abnormal mitotic spindles, leading to decreased proliferation and apoptosis in a range of human tumor cell lines. Alisertib has shown single-agent antitumor activity in animal xenograft models and promising antitumor activity alone or in combination with other agents in patients with solid and hematologic cancers, and T-cell lymphomas in particular. It is currently being tested in randomized controlled Phase III trials in relapsed/refractory peripheral T-cell lymphoma.

• Authors: Eve Gallop-Evans
• Journal: Future oncology (London, England) (Future Oncol) Vol. 11 Issue 18 Pg. 2515-24 (Sep 2015) ISSN: 1744-8301 [Electronic] England
• PMID: 26344156 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Azepines
• MLN 8237
• Protein Kinase Inhibitors
• Pyrimidines

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Azepines (pharmacology, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Drug Discovery
• Drug Evaluation, Preclinical
• Humans
• Lymphoma, T-Cell, Peripheral (drug therapy, mortality, pathology)
• Neoplasm Recurrence, Local
• Protein Kinase Inhibitors (pharmacology, therapeutic use)
• Pyrimidines (pharmacology, therapeutic use)
• Treatment Outcome